Sylvie Lantuejoul
University of Grenoble
CancerInternal medicineRadiologySurgeryPathologyOncologyImmunohistochemistryBiopsyLung cancerMesotheliomaCarcinomaLungCrizotinibPD-L1AdenocarcinomaGynecologyCancer researchCarcinogenesisMedicineBiology
292Publications
65H-index
10.3kCitations
Publications 295
Newest
#1Lise Mangiante (IARC: International Agency for Research on Cancer)H-Index: 2
#2Nicolas Alcala (IARC: International Agency for Research on Cancer)H-Index: 11
Last. Nolwenn Le Stang (French Institute of Health and Medical Research)H-Index: 12
view all 58 authors...
Summary null Malignant Pleural Mesothelioma (MPM) is an aggressive cancer with rising incidence and challenging clinical management. Using the largest series of whole-genome sequencing data integrated with transcriptomic and epigenomic data using multi-omic factor analysis, we demonstrate that MPM heterogeneity arises from four sources of variation: tumor cell morphology, ploidy, adaptive immune response, and CpG island methylator phenotype. Previous genomic studies focused on describing only th...
Source
#1Wendy A Cooper (RPA: Royal Prince Alfred Hospital)H-Index: 35
#2Sylvie Lantuejoul (UGA: University of Grenoble)H-Index: 65
Last. Mari Mino-Kenudson (Harvard University)H-Index: 93
view all 3 authors...
Source
#1Sylvie Lantuejoul (UGA: University of Grenoble)H-Index: 65
#2Daniel Pissaloux (UCBL: Claude Bernard University Lyon 1)H-Index: 10
Last. Anne McLeer (UGA: University of Grenoble)H-Index: 2
view all 4 authors...
NUT carcinoma of the thorax is a rare and very aggressive tumor, whose definition is based on the demonstration of a nuclear protein in testis (NUTM1; also known as NUT) gene fusion on 15q14 with different partners from the bromodomain-containing proteins gene family. This fusion results in an activation of MYC oncoprotein responsible for the tumor's aggressivity. NUT carcinoma arises preferentially in young adults, presenting a large thoracic mass frequently associated with lymph nodes, bone or...
Source
NUT carcinoma (NC), formerly known as NUT midline carcinoma, is a rare and very aggressive cancer. It is genetically defined by the presence of acquired chromosomal rearrangement of the NUTM1 (NUclear protein in Testis Midline carcinoma family member 1) gene at chromosome 15q14 with a member of the bromodomain-containing protein (BRD) family gene, usually BRD4. Although primarily reported in the head and neck, and mediastinum locations of younger individuals, it is now established that NC arises...
Source
ABSTRACT INTRODUCTION Patients with advanced-stage non-small cell lung cancer (NSCLC) whose tumors harbor an anaplastic lymphoma kinase (ALK) gene rearrangement benefit from treatment with multiple ALK inhibitors (ALKi). Approximately 30% of tumor biopsies contain insufficient tissue for successful ALK molecular characterization. This study evaluated the added value of analyzing circulating tumor cells (CTCs) as a surrogate to ALK tissue analysis and as a function of the response to ALKi. PATIEN...
3 CitationsSource
#1A-M.C. Dingemans (EUR: Erasmus University Rotterdam)H-Index: 10
#2Martin Früh (Kantonsspital St. Gallen)H-Index: 18
Last. M. ReckH-Index: 28
view all 14 authors...
12 CitationsSource
Abstract Background PD-L1 immunohistochemistry (IHC) is required to determine eligibility for pembrolizumab monotherapy in advanced non-small cell lung cancer (NSCLC) worldwide and for several other indications depending on the country. Four assays have been approved/CE-IVD marked, but PD-L1 IHC seems diversely implemented across regions and laboratories with the application of laboratory-developed tests (LDTs). Method To assess practice of PD-L1 IHC and identify issues and disparities, the IASL...
Source
Source
#1Audrey PetitH-Index: 1
#2Sylvie LantuejoulH-Index: 65
Last. Dominique PlantazH-Index: 46
view all 11 authors...
1 CitationsSource
#1Wei-Chin ChangH-Index: 1
#2Yu Zhi Zhang (NIH: National Institutes of Health)H-Index: 2
Last. Andrew G. Nicholson (NIH: National Institutes of Health)H-Index: 123
view all 13 authors...
Aims Mucinous adenocarcinoma arising in congenital pulmonary airway malformation (CPAM) is a rare complication, with little being known about its natural course. The aims of this article are to describe a series of mucinous adenocarcinomas arising from CPAMs, and present their clinicopathological features, genetics, and clinical outcome. Methods and results Thirty-seven cases were collected within a 34-year period, and the subtype of adenocarcinoma and CPAM, tumour location, stage, growth patter...
2 CitationsSource